Anthelmintic Drugs Market Size to Hit USD 9.01 Billion by 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Anthelmintic Drugs Market

5.1. COVID-19 Landscape: Anthelmintic Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Anthelmintic Drugs Market, By Drug Class

8.1. Anthelmintic Drugs Market Revenue and Volume Forecast, by Drug Class

8.1.1. Benzimidazoles (Albendazole, Mebendazole)

8.1.1.1. Market Revenue and Volume Forecast

8.1.2. Macrocyclic Lactones (Ivermectin, Moxidectin)

8.1.2.1. Market Revenue and Volume Forecast

8.1.3. Imidazothiazoles & Tetrahydropyrimidines (Levamisole, Pyrantel).

8.1.3.1. Market Revenue and Volume Forecast

Chapter 9. Global Anthelmintic Drugs Market, By Application

9.1. Anthelmintic Drugs Market Revenue and Volume Forecast, by Application

9.1.1. Human Health

9.1.1.1. Market Revenue and Volume Forecast

9.1.2. Veterinary Medicine

9.1.2.1. Market Revenue and Volume Forecast

Chapter 10. Global Anthelmintic Drugs Market, By Target Parasite

10.1. Anthelmintic Drugs Market Revenue and Volume Forecast, by Target Parasite

10.1.1. Nematodes (Roundworms)

10.1.1.1. Market Revenue and Volume Forecast

10.1.2. Cestodes (Tapeworms)

10.1.2.1. Market Revenue and Volume Forecast

10.1.3. Trematodes (Flukes)

10.1.3.1. Market Revenue and Volume Forecast

Chapter 11. Global Anthelmintic Drugs Market, By Distribution Channel

11.1. Anthelmintic Drugs Market Revenue and Volume Forecast, by Distribution Channel

11.1.1. Drug Stores & Retail Pharmacies

11.1.1.1. Market Revenue and Volume Forecast

11.1.2. Hospital Pharmacies.

11.1.2.1. Market Revenue and Volume Forecast

11.1.3. Public Health Programs

11.1.3.1. Market Revenue and Volume Forecast

Chapter 12. Global Anthelmintic Drugs Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Volume Forecast, by Drug Class

12.1.2. Market Revenue and Volume Forecast, by Application

12.1.3. Market Revenue and Volume Forecast, by Target Parasite

12.1.4. Market Revenue and Volume Forecast, by Distribution Channel

12.1.5. U.S.

12.1.5.1. Market Revenue and Volume Forecast, by Drug Class

12.1.5.2. Market Revenue and Volume Forecast, by Application

12.1.5.3. Market Revenue and Volume Forecast, by Target Parasite

12.1.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.1.6. Rest of North America

12.1.6.1. Market Revenue and Volume Forecast, by Drug Class

12.1.6.2. Market Revenue and Volume Forecast, by Application

12.1.6.3. Market Revenue and Volume Forecast, by Target Parasite

12.1.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2. Europe

12.2.1. Market Revenue and Volume Forecast, by Drug Class

12.2.2. Market Revenue and Volume Forecast, by Application

12.2.3. Market Revenue and Volume Forecast, by Target Parasite

12.2.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.5. UK

12.2.5.1. Market Revenue and Volume Forecast, by Drug Class

12.2.5.2. Market Revenue and Volume Forecast, by Application

12.2.5.3. Market Revenue and Volume Forecast, by Target Parasite

12.2.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.6. Germany

12.2.6.1. Market Revenue and Volume Forecast, by Drug Class

12.2.6.2. Market Revenue and Volume Forecast, by Application

12.2.6.3. Market Revenue and Volume Forecast, by Target Parasite

12.2.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.7. France

12.2.7.1. Market Revenue and Volume Forecast, by Drug Class

12.2.7.2. Market Revenue and Volume Forecast, by Application

12.2.7.3. Market Revenue and Volume Forecast, by Target Parasite

12.2.7.4. Market Revenue and Volume Forecast, by Distribution Channel

12.2.8. Rest of Europe

12.2.8.1. Market Revenue and Volume Forecast, by Drug Class

12.2.8.2. Market Revenue and Volume Forecast, by Application

12.2.8.3. Market Revenue and Volume Forecast, by Target Parasite

12.2.8.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3. APAC

12.3.1. Market Revenue and Volume Forecast, by Drug Class

12.3.2. Market Revenue and Volume Forecast, by Application

12.3.3. Market Revenue and Volume Forecast, by Target Parasite

12.3.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.5. India

12.3.5.1. Market Revenue and Volume Forecast, by Drug Class

12.3.5.2. Market Revenue and Volume Forecast, by Application

12.3.5.3. Market Revenue and Volume Forecast, by Target Parasite

12.3.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.6. China

12.3.6.1. Market Revenue and Volume Forecast, by Drug Class

12.3.6.2. Market Revenue and Volume Forecast, by Application

12.3.6.3. Market Revenue and Volume Forecast, by Target Parasite

12.3.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.7. Japan

12.3.7.1. Market Revenue and Volume Forecast, by Drug Class

12.3.7.2. Market Revenue and Volume Forecast, by Application

12.3.7.3. Market Revenue and Volume Forecast, by Target Parasite

12.3.7.4. Market Revenue and Volume Forecast, by Distribution Channel

12.3.8. Rest of APAC

12.3.8.1. Market Revenue and Volume Forecast, by Drug Class

12.3.8.2. Market Revenue and Volume Forecast, by Application

12.3.8.3. Market Revenue and Volume Forecast, by Target Parasite

12.3.8.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4. MEA

12.4.1. Market Revenue and Volume Forecast, by Drug Class

12.4.2. Market Revenue and Volume Forecast, by Application

12.4.3. Market Revenue and Volume Forecast, by Target Parasite

12.4.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.5. GCC

12.4.5.1. Market Revenue and Volume Forecast, by Drug Class

12.4.5.2. Market Revenue and Volume Forecast, by Application

12.4.5.3. Market Revenue and Volume Forecast, by Target Parasite

12.4.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.6. North Africa

12.4.6.1. Market Revenue and Volume Forecast, by Drug Class

12.4.6.2. Market Revenue and Volume Forecast, by Application

12.4.6.3. Market Revenue and Volume Forecast, by Target Parasite

12.4.6.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.7. South Africa

12.4.7.1. Market Revenue and Volume Forecast, by Drug Class

12.4.7.2. Market Revenue and Volume Forecast, by Application

12.4.7.3. Market Revenue and Volume Forecast, by Target Parasite

12.4.7.4. Market Revenue and Volume Forecast, by Distribution Channel

12.4.8. Rest of MEA

12.4.8.1. Market Revenue and Volume Forecast, by Drug Class

12.4.8.2. Market Revenue and Volume Forecast, by Application

12.4.8.3. Market Revenue and Volume Forecast, by Target Parasite

12.4.8.4. Market Revenue and Volume Forecast, by Distribution Channel

12.5. Latin America

12.5.1. Market Revenue and Volume Forecast, by Drug Class

12.5.2. Market Revenue and Volume Forecast, by Application

12.5.3. Market Revenue and Volume Forecast, by Target Parasite

12.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.5.5. Brazil

12.5.5.1. Market Revenue and Volume Forecast, by Drug Class

12.5.5.2. Market Revenue and Volume Forecast, by Application

12.5.5.3. Market Revenue and Volume Forecast, by Target Parasite

12.5.5.4. Market Revenue and Volume Forecast, by Distribution Channel

12.5.6. Rest of LATAM

12.5.6.1. Market Revenue and Volume Forecast, by Drug Class

12.5.6.2. Market Revenue and Volume Forecast, by Application

12.5.6.3. Market Revenue and Volume Forecast, by Target Parasite

12.5.6.4. Market Revenue and Volume Forecast, by Distribution Channel

Chapter 13. Company Profiles

13.1. Novartis AG

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial PerDrug Classance

13.1.4. Recent Initiatives

13.2. Merck & Co., Inc.

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial PerDrug Classance

13.2.4. Recent Initiatives

13.3. Zoetis Inc.

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial PerDrug Classance

13.3.4. Recent Initiatives

13.4. Boehringer Ingelheim GmbH

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial PerDrug Classance

13.4.4. Recent Initiatives

13.5. Bayer AG

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial PerDrug Classance

13.5.4. Recent Initiatives

13.6. GlaxoSmithKline plc (GSK)

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial PerDrug Classance

13.6.4. Recent Initiatives

13.7. Sanofi

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial PerDrug Classance

13.7.4. Recent Initiatives

13.8. Elanco Animal Health

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial PerDrug Classance

13.8.4. Recent Initiatives

13.9. Virbac S.A.

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial PerDrug Classance

13.9.4. Recent Initiatives

13.10. Novartis AG

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial PerDrug Classance

13.10.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

Answer : The anthelmintic drugs market size is expected to increase from USD 4.06 billion in 2025 to USD 9.01 billion by 2035.

Answer : The anthelmintic drugs market is expected to grow at a compound annual growth rate (CAGR) of around 8.30% from 2026 to 2035.

Answer : The driving factors of the anthelmintic drugs market are the market spans human health, veterinary medicine, and public health interventions, reflecting its broad and essential application.

Answer : North America region will lead the global anthelmintic drugs market during the forecast period 2026 to 2035.